Literature DB >> 24502300

Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedema.

Nele Devoogdt1, Steven Pans, An De Groef, Inge Geraerts, Marie-Rose Christiaens, Patrick Neven, Ignace Vergote, Marijke Van Kampen.   

Abstract

BACKGROUND: Compared to volume/circumference measurements to diagnose lymphedema, thickening and disturbance of echogenicity of cutis and subcutis associated with the development of lymphedema is measured directly by ultrasonography. The aim of the present study was to investigate the evolution of thickness and echogenicity of cutis and subcutis of the lower and upper arm after axillary dissection for breast cancer and compare patients with and without arm lymphedema. METHODS AND
RESULTS: Immediately after the surgery and at 6 and 12 months post-surgery, 42 patients received an ultrasonography of both arms, at the wrist, ventral and dorsal side of the lower arm, and biceps and triceps side of the upper arm. Thickness and echogenicity of cutis and subcutis were determined. Lymphedema was defined as 5.0% or more increase compare to the preoperative value. Eighteen patients had developed lymphedema of the lower arm, and 24 patients of the upper arm. Thickness of the cutis decreased significantly during the postoperative period on the healthy and affected side as well. The difference of cutis thickness between affected and healthy side increased postoperatively in patients with lymphedema and decreased in patients without lymphedema at the wrist and dorsal side of the lower arm. Patients with lymphedema had more frequent disturbance of echogenicity of the cutis at all measurement points. In exception of the triceps, thickness and echogenicity of the subcutis is less obvious disturbed. Sensitivity to detect arm lymphedema by ultrasonography was acceptable for increased subcutis thickness at the ventral lower arm and triceps and disturbed cutis echogenicity at the wrist (67%-100%). Sensitivity for the other measurements was bad. Specificity was for all measurements acceptable (59%-100%).
CONCLUSION: Ultrasonography may be useful to diagnose lymphedema developing after axillary dissection for breast cancer. However, it cannot be used as a separate diagnostic test for lymphedema.

Entities:  

Mesh:

Year:  2014        PMID: 24502300     DOI: 10.1089/lrb.2013.0028

Source DB:  PubMed          Journal:  Lymphat Res Biol        ISSN: 1539-6851            Impact factor:   2.589


  5 in total

1.  Diagnosis of Upper-Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of APTA.

Authors:  Kimberly Levenhagen; Claire Davies; Marisa Perdomo; Kathryn Ryans; Laura Gilchrist
Journal:  Rehabil Oncol       Date:  2017-06-30

Review 2.  Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of the American Physical Therapy Association.

Authors:  Kimberly Levenhagen; Claire Davies; Marisa Perdomo; Kathryn Ryans; Laura Gilchrist
Journal:  Phys Ther       Date:  2017-07-01

3.  Skin Layer Thickness and Shear Wave Elastography Changes Induced by Intensive Decongestive Treatment of Lower Limb Lymphedema.

Authors:  Merriem Zarrad; Claire Duflos; Gregory Marin; Murielle Benhamou; Jean-Pierre Laroche; Michel Dauzat; Isabelle Quéré; Sandrine Mestre-Godin
Journal:  Lymphat Res Biol       Date:  2021-12-22       Impact factor: 2.589

4.  Relationship between lymphedema after breast cancer treatment and biophysical characteristics of the affected tissue.

Authors:  Carla S Perez; Carolina Mestriner; Leticia T N Ribeiro; Felipe W Grillo; Tenysson W Lemos; Antônio A Carneiro; Rinaldo Roberto de Jesus Guirro; Elaine C O Guirro
Journal:  PLoS One       Date:  2022-04-20       Impact factor: 3.752

5.  Diagnostic Accuracy of Clinical Measures Considering Segmental Tissue Composition and Volume Changes of Breast Cancer-Related Lymphedema.

Authors:  Eun Joo Yang; Seoung Yeon Kim; Woo Hyung Lee; Jae-Young Lim; Jaebong Lee
Journal:  Lymphat Res Biol       Date:  2018-01-17       Impact factor: 2.589

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.